MCID: PST046
MIFTS: 55

Post-Transplant Lymphoproliferative Disease

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Post-Transplant Lymphoproliferative Disease

MalaCards integrated aliases for Post-Transplant Lymphoproliferative Disease:

Name: Post-Transplant Lymphoproliferative Disease 38 53 59
Post-Transplant Lymphoproliferative Disorder 73
Ptld 59

Characteristics:

Orphanet epidemiological data:

59
post-transplant lymphoproliferative disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages;

Classifications:



External Ids:

Orphanet 59 ORPHA70568
UMLS via Orphanet 74 C0432487
ICD10 via Orphanet 34 D47.9
UMLS 73 C0432487

Summaries for Post-Transplant Lymphoproliferative Disease

MalaCards based summary : Post-Transplant Lymphoproliferative Disease, also known as post-transplant lymphoproliferative disorder, is related to hematopoietic stem cell transplantation and toxoplasmosis. An important gene associated with Post-Transplant Lymphoproliferative Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include liver, b cells and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Post-transplant lymphoproliferative disorder (PTLD) is the name given to a B-cell proliferation due to... more...

Related Diseases for Post-Transplant Lymphoproliferative Disease

Diseases related to Post-Transplant Lymphoproliferative Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
# Related Disease Score Top Affiliating Genes
1 hematopoietic stem cell transplantation 31.1 IL10 IL6 TNF
2 toxoplasmosis 30.3 IL10 IL6 TNF
3 pneumonia 30.1 IL10 IL6 TNF
4 graft-versus-host disease 29.7 IL10 IL1A IL6 TNF
5 tonsillitis 29.5 IL1A IL6 LTA TNF
6 myeloma, multiple 29.4 B2M CASP8 IL6 TNF
7 lyme disease 11.2
8 punctate inner choroidopathy 10.9 IL10 TNF
9 tropical endomyocardial fibrosis 10.9 IL10 TNF
10 microscopic polyangiitis 10.8 IL10 TNF
11 multifocal choroiditis 10.8 IL10 TNF
12 tungiasis 10.8 IL10 TNF
13 endomyocardial fibrosis 10.8 IL10 TNF
14 skin sarcoidosis 10.8 TNF TNFRSF1B
15 immunoglobulin a deficiency 1 10.7 IL10 LTA
16 rheumatoid lung disease 10.7 TNF TNFRSF1B
17 posterior scleritis 10.7 TNF TNFRSF10A
18 eye lymphoma 10.7 IL10 IL6
19 scorpion envenomation 10.7 IL6 TNF
20 acute transverse myelitis 10.7 IL10 IL6
21 scleral disease 10.7 TNF TNFRSF1B
22 pustulosis of palm and sole 10.7 TNF TNFRSF1B
23 extramedullary plasmacytoma 10.7 B2M IL6
24 leukomalacia 10.6 IL6 TNF
25 angioimmunoblastic lymphadenopathy with dysproteinemia 10.6 IL6 TNF
26 panuveitis 10.6 IL10 TNF TNFRSF1B
27 chondromalacia 10.6 TNFRSF10A TNFRSF1B
28 choroiditis 10.6 IL10 TNF
29 chronic gonococcal salpingitis 10.6 TNF TNFRSF1A TNFRSF1B
30 retinitis pigmentosa 75 10.6 TNF TNFRSF1A
31 inflammatory bowel disease 25, autosomal recessive 10.6 IL10 IL10RA
32 periodic fever, familial, autosomal dominant 10.6 TNF TNFRSF1A TNFRSF1B
33 acute salpingitis 10.6 TNF TNFRSF1A TNFRSF1B
34 critical limb ischemia 10.6 IL6 TNF
35 chronic salpingitis 10.6 TNF TNFRSF1A TNFRSF1B
36 peroneal neuropathy 10.5 TNF TNFRSF1B
37 guillain-barre syndrome 10.5 TNF TNFRSF1A TNFRSF1B
38 transient hypogammaglobulinemia 10.5 IL10 LTA TNF
39 idiopathic achalasia 10.5 IL10 LTA TNF
40 leprosy 3 10.5 IL10 SLC11A1 TNF
41 spondylarthropathy 10.5 B2M LTA TNF
42 scabies 10.5 IL10 IL1A
43 lymphadenitis 10.5 IL10 SLC11A1 TNF
44 cutaneous leishmaniasis 10.5 IL10 SLC11A1 TNF
45 pericoronitis 10.5 TNFRSF1A TNFRSF1B
46 listeriosis 10.5 IL10 IL6 TNF
47 transverse myelitis 10.5 IL10 IL6 TNF
48 intermediate uveitis 10.5 IL10 IL6 TNF
49 demyelinating disease 10.5 IL10 TNF TNFRSF1A
50 eales disease 10.5 IL10 IL6 TNF

Graphical network of the top 20 diseases related to Post-Transplant Lymphoproliferative Disease:



Diseases related to Post-Transplant Lymphoproliferative Disease

Symptoms & Phenotypes for Post-Transplant Lymphoproliferative Disease

GenomeRNAi Phenotypes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 TNFRSF1A CASP8 TNFRSF1B FADD TNFSF10 IL10
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 TNFRSF10A TNFRSF1A CASP8 TNFRSF1B FADD TNFSF10

MGI Mouse Phenotypes related to Post-Transplant Lymphoproliferative Disease:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 TNF TNFRSF1B TNFRSF10A SLC11A1 TNFRSF1A TNFSF10
2 cardiovascular system MP:0005385 10.35 TNFRSF1A TNF TNFRSF1B TNFSF10 FADD B2M
3 immune system MP:0005387 10.35 TNF TNFRSF1B TNFRSF10A SLC11A1 TNFRSF1A TNFSF10
4 homeostasis/metabolism MP:0005376 10.34 TNFRSF1A TNF TNFRSF1B TNFRSF10A TNFSF10 FADD
5 endocrine/exocrine gland MP:0005379 10.31 TNFRSF1A TNF TNFRSF1B TNFRSF10A TNFSF10 FADD
6 cellular MP:0005384 10.3 TNFRSF1A TNF TNFRSF10A TNFRSF1B FADD B2M
7 growth/size/body region MP:0005378 10.22 TNFRSF1A TNF TNFRSF1B FADD B2M CASP8
8 mortality/aging MP:0010768 10.22 SLC11A1 TNFRSF1A TNF TNFRSF1B TNFRSF10A TNFSF10
9 digestive/alimentary MP:0005381 10.2 TNFRSF1A TNF TNFRSF1B SLC11A1 FADD B2M
10 liver/biliary system MP:0005370 10.17 TNFRSF1A TNF TNFRSF1B TNFSF10 FADD B2M
11 integument MP:0010771 10.11 TNFRSF1A TNF TNFRSF1B B2M IL10 CASP8
12 neoplasm MP:0002006 10.1 TNF TNFRSF1B TNFRSF10A SLC11A1 TNFRSF1A TNFSF10
13 muscle MP:0005369 9.97 TNFRSF1A TNF TNFRSF1B FADD IL10 CASP8
14 nervous system MP:0003631 9.96 TNFRSF1A TNF TNFRSF1B FADD B2M CASP8
15 respiratory system MP:0005388 9.76 TNFRSF1A TNF TNFRSF1B IL10 CASP8 IL6
16 skeleton MP:0005390 9.61 TNFRSF1A TNF TNFSF10 TNFRSF1B FADD IL10
17 vision/eye MP:0005391 9.17 TNFRSF1A TNF LTA TNFRSF1B IL6 IL1R1

Drugs & Therapeutics for Post-Transplant Lymphoproliferative Disease

Drugs for Post-Transplant Lymphoproliferative Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 2 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 2 23214-92-8 31703
3
Fludarabine Approved Phase 4,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
5
Vidarabine Approved, Investigational Phase 4,Phase 2,Phase 1 24356-66-9 32326 21704
6
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 4,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
8
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
9
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
10
Doxil Approved June 1999 Phase 4,Phase 2 31703
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Alkylating Agents Phase 4,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Infective Agents Phase 4,Phase 2,Phase 1
17 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
20 Antiviral Agents Phase 4,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 2
22 Calcineurin Inhibitors Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Liver Extracts Phase 4,Phase 2,Phase 3,Not Applicable
24 Antitubercular Agents Phase 4,Phase 2,Phase 1
25
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
26
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
27
Pancrelipase Approved, Investigational Phase 3,Phase 2 53608-75-6
28
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
29
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33 Adjuvants, Immunologic Phase 2, Phase 3
34 diuretics Phase 2, Phase 3
35 Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1
36 Hormones Phase 2, Phase 3,Phase 3,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 3,Phase 1
38 pancreatin Phase 3,Phase 2
39 Antiemetics Phase 3,Phase 2,Phase 1
40 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
42 Autonomic Agents Phase 3,Phase 2,Phase 1
43 Dermatologic Agents Phase 3,Phase 2,Phase 1
44 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
45 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
46 glucocorticoids Phase 3,Phase 2,Phase 1
47 Methylprednisolone acetate Phase 3,Phase 2,Phase 1
48 Methylprednisolone Hemisuccinate Phase 3,Phase 2,Phase 1
49 Neuroprotective Agents Phase 3,Phase 2,Phase 1
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4 fludarabine, cyclophosphamide, doxorubicin, rituximab
2 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4 MMF (Cellcept);placebo
3 Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation Unknown status NCT00033475 Phase 3
4 Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study Completed NCT02451033 Phase 2, Phase 3 standard medical therapy;G-CSF;Growth Hormone
5 Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab Recruiting NCT03392142 Phase 3
6 Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy Recruiting NCT03394365 Phase 3
7 To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids Not yet recruiting NCT03371667 Phase 3 Methotrexate;Placebo
8 Bortezomib Plus Rituximab for EBV+ PTLD Completed NCT01058239 Phase 2 bortezomib;rituximab
9 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder Completed NCT00064246 Phase 1, Phase 2
10 Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Completed NCT00307125 Phase 2 Rituximab plus immunosuppression;Placebo plus immunosuppression
11 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Completed NCT01565616 Phase 2 Conditioning Regimen with Bone Marrow Transplant
12 Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy Recruiting NCT02042391 Phase 2 Rituximab sc;Rituximab sc consolidation;Rituximab sc combined with CHOP chemotherapy;Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx
13 Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder Recruiting NCT02900976 Phase 2
14 Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma Recruiting NCT01964755 Phase 2 Doxorubicin;Methotrexate;Leucovorin;Zidovudine;Rituximab
15 Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas Recruiting NCT02763254 Phase 2
16 Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation Active, not recruiting NCT00066469 Phase 2 cyclophosphamide;methylprednisolone;prednisone
17 Donor Lymphocyte Infusion After Alternative Donor Transplantation Terminated NCT01027702 Phase 1, Phase 2
18 Pilot Study of Unrelated Cord Blood Transplantation Terminated NCT00916045 Phase 2 Thiotepa;Fludarabine;Intravenous busulphan;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF);Fludarabine;Cyclophosphamide;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF);Fludarabine;Melphalan;Thymoglobulin;Ciclosporin;Mycophenolate mofetil (MMF)
19 Multi-Drug Desensitization Protocol for Heart Transplant Candidates Terminated NCT01556347 Phase 2 Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
20 Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation Terminated NCT01790594 Phase 2 methylprednisolone;Tacrolimus;Mycophenolate mofetil
21 Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease Recruiting NCT02867800 Phase 1 Diphenhydramine;Acetaminophen;Methylprednisolone;Meperidine;Alemtuzumab;Thymoglobulin;Fludarabine;Melphalan;Thiotepa;Cyclosporine;Tacrolimus;Methotrexate;Abatacept;Sirolimus;Mycophenolate Mofetil
22 Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation Terminated NCT00087009 Phase 1
23 Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs Unknown status NCT00947492 Not Applicable
24 Virus Surveillance in Pediatric Solid Organ Transplant Recipients Unknown status NCT00886158
25 Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients Completed NCT01375127 Tofacitinib;Tofacitinib
26 MMF After Pediatric Liver Transplantation Completed NCT00367146 Not Applicable MMF
27 Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists Completed NCT00859131 Not Applicable Rabbit Antithymocyte globulin;Daclizumab
28 Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03343834 Not Applicable
29 Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients Recruiting NCT02505789
30 HLA-Identical Sibling Renal Transplant Tolerance Active, not recruiting NCT00619528 Not Applicable
31 Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant Not yet recruiting NCT03131934 Early Phase 1
32 Relationship Between EBV and PTLD Terminated NCT00215033

Search NIH Clinical Center for Post-Transplant Lymphoproliferative Disease

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Post-Transplant Lymphoproliferative Disease:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Post-Transplant Lymphoproliferative Disease:
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Post-Transplant Lymphoproliferative Disease

Anatomical Context for Post-Transplant Lymphoproliferative Disease

MalaCards organs/tissues related to Post-Transplant Lymphoproliferative Disease:

41
Liver, B Cells, Bone, Kidney, Heart, Bone Marrow, T Cells

Publications for Post-Transplant Lymphoproliferative Disease

Articles related to Post-Transplant Lymphoproliferative Disease:

(show top 50) (show all 162)
# Title Authors Year
1
Post-transplant lymphoproliferative disease after liver transplantation. ( 29313699 )
2018
2
Post-transplant lymphoproliferative disease with features of cutaneous natural killer/T-cell lymphoma. ( 29380362 )
2018
3
Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. ( 29342279 )
2018
4
Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort. ( 29071779 )
2018
5
Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation. ( 29949208 )
2018
6
Immunotherapy with the trifunctional anti-CD20a88A9a88anti-CD3 antibody FBTA05 in a patient with relapsed t(8;14)-positive post-transplant lymphoproliferative disease. ( 28093004 )
2017
7
Post-transplant lymphoproliferative disease in liver transplant recipients. ( 28508661 )
2017
8
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
9
Post-transplant lymphoproliferative disease is associated with early sternotomy and left ventricular hypoplasia during infancy: a population-based retrospective review. ( 28780922 )
2017
10
Graft outcomes following diagnosis of post-transplant lymphoproliferative disease in pediatric kidney recipients: a retrospective study. ( 28906028 )
2017
11
Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study. ( 28383790 )
2017
12
Recent advances in the risk factors, diagnosis and management of Epstein-Barr virus post-transplant lymphoproliferative disease. ( 29421230 )
2016
13
Comment on: Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26944670 )
2016
14
Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. ( 27467959 )
2016
15
The Role of Antiviral Prophylaxis for the Prevention of Epstein Barr Virus Associated Post-transplant Lymphoproliferative Disease in Solid Organ Transplant Recipients: A Systematic Review. ( 27545492 )
2016
16
Persistent Epstein-Barr viral load in Epstein-Barr viral naA^ve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease. ( 28058224 )
2016
17
Early Post-transplant Lymphoproliferative Disease in the Donor Ureter Without Systemic Involvement: A Case Report. ( 26361705 )
2015
18
How Should We Treat Early Post-Transplant Lymphoproliferative Disease After Heart Transplantation? ( 26549285 )
2015
19
Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lymphoproliferative disease of Hodgkin's type: a diagnostic challenge. ( 26239296 )
2015
20
Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. ( 25843801 )
2015
21
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease. ( 25845981 )
2015
22
Post-transplant lymphoproliferative disease and other malignancies after pediatric cardiac transplantation: an evolving landscape. ( 26262461 )
2015
23
Successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation - a case study. ( 26155195 )
2015
24
Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors. ( 26279197 )
2015
25
Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: An update. ( 25936966 )
2015
26
FDG-PET/CT in Abdominal Post-Transplant Lymphoproliferative Disease. ( 26544161 )
2015
27
Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. ( 25686696 )
2015
28
Array CGH-based analysis of post-transplant plasmacytic hyperplasia reveals 'intact genomes' arguing against categorizing it as part of the post-transplant lymphoproliferative disease spectrum. ( 25041332 )
2014
29
Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: A single-center experience. ( 24399278 )
2014
30
CD30 in pediatric post-transplant lymphoproliferative disease after solid organ transplant: characterization of a new therapeutic target. ( 25242095 )
2014
31
Risk factors for Epstein Barr virus related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. ( 24056821 )
2013
32
Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. ( 23802715 )
2013
33
Isolated post-transplantation lymphoproliferative disease involving the breast and axilla as peripheral T-cell lymphoma. ( 24043963 )
2013
34
Breast involvement with post-transplant lymphoproliferative disease in a renal transplant recipient. ( 24034058 )
2013
35
Epistaxis in a kidney transplant recipient: an uncommon presentation of post-transplant lymphoproliferative disease. ( 23577919 )
2013
36
Splenectomy prior to allogeneic hematopoietic SCT increases the risk of post-transplant lymphoproliferative disease. ( 24335998 )
2013
37
Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoproliferative disease following renal transplantation. ( 23666631 )
2013
38
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. ( 23737188 )
2013
39
Rapidly progressive post-transplant lymphoproliferative disease following withdrawal of sirolimus. ( 23498038 )
2012
40
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. ( 22711849 )
2012
41
Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. ( 21584931 )
2012
42
T-cell therapy in the treatment of post-transplant lymphoproliferative disease. ( 22801669 )
2012
43
Graft rejection in pediatric liver transplant patients with Epstein-Barr viremia and post-transplant lymphoproliferative disease. ( 22554096 )
2012
44
Post-transplant lymphoproliferative disease of donor origin, following haematopoietic stem cell transplantation in a patient with blastic plasmacytoid dendritic cell neoplasm. ( 22915052 )
2012
45
CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. ( 21559814 )
2011
46
Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants. ( 21056103 )
2011
47
Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. ( 21518001 )
2011
48
Adult post-transplant lymphoproliferative disease in the liver graft in patients with recurrent hepatitis C. ( 21555941 )
2011
49
CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation. ( 21275950 )
2011
50
Fludarabine, cyclophosphamide, doxorubicin (FCD), and rituximab: a remission induction therapy for aggressive pediatric post-transplant lymphoproliferative disease (PTLD). ( 21294246 )
2011

Variations for Post-Transplant Lymphoproliferative Disease

Expression for Post-Transplant Lymphoproliferative Disease

Search GEO for disease gene expression data for Post-Transplant Lymphoproliferative Disease.

Pathways for Post-Transplant Lymphoproliferative Disease

Pathways related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 B2M CASP8 FADD IL10 IL10RA IL1A
2
Show member pathways
13.87 CASP8 FADD IL6 LTA TNF TNFRSF10A
3
Show member pathways
13.87 CASP8 FADD IL10 IL10RA IL1A IL1R1
4
Show member pathways
13.71 CASP8 IL10 IL10RA IL1A IL1R1 IL6
5
Show member pathways
13.53 IL10 IL10RA IL1A IL1R1 IL6 LTA
6
Show member pathways
13.41 B2M IL10 IL10RA IL1A IL1R1 IL6
7
Show member pathways
13.36 FADD IL10 IL10RA IL1A IL1R1 IL6
8
Show member pathways
13.1 CASP8 IL10 IL10RA IL1A IL1R1 IL6
9
Show member pathways
13.04 CASP8 FADD IL10 IL6 TNF TNFRSF1A
10
Show member pathways
12.99 CASP8 FADD LTA TNF TNFRSF10A TNFRSF1A
11
Show member pathways
12.98 CASP8 FADD IL6 TNF TNFRSF1A
12
Show member pathways
12.98 CASP8 FADD IL6 TNF TNFRSF10A TNFRSF1A
13
Show member pathways
12.92 IL6 LTA TNF TNFRSF1A TNFRSF1B
14
Show member pathways
12.85 CASP8 FADD IL1R1 LTA TNF TNFRSF10A
15
Show member pathways
12.82 CASP8 FADD IL1A IL6 LTA TNF
16 12.8 CASP8 IL1A IL1R1 TNF TNFRSF1A
17
Show member pathways
12.79 FADD IL1A IL1R1 IL6 LTA TNF
18
Show member pathways
12.74 IL1A IL1R1 LTA TNF TNFRSF1A TNFRSF1B
19
Show member pathways
12.72 IL10 IL10RA IL1A IL6 LTA TNF
20
Show member pathways
12.71 CASP8 FADD IL1R1 TNFRSF10A TNFSF10
21
Show member pathways
12.62 CASP8 FADD IL6 TNF TNFRSF1A
22 12.62 B2M IL10 TNF TNFRSF1A TNFRSF1B
23
Show member pathways
12.59 IL10 IL10RA IL6 TNF
24
Show member pathways
12.58 CASP8 FADD LTA TNF TNFRSF1A TNFRSF1B
25
Show member pathways
12.51 IL10 IL1A IL1R1 IL6 TNF
26 12.49 IL1R1 IL6 LTA TNF TNFRSF1A
27
Show member pathways
12.45 IL10 IL1A IL6 TNF
28
Show member pathways
12.44 B2M CASP8 FADD IL10 IL10RA IL1A
29
Show member pathways
12.42 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
30
Show member pathways
12.37 CASP8 FADD IL6 TNF
31
Show member pathways
12.36 CASP8 IL10 IL10RA IL1A TNF TNFRSF1A
32
Show member pathways
12.34 CASP8 FADD TNFRSF10A TNFSF10
33
Show member pathways
12.34 IL10 IL1R1 IL6 LTA TNF
34 12.34 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
35
Show member pathways
12.32 IL1A IL1R1 IL6 TNF
36
Show member pathways
12.31 CASP8 FADD IL1A TNF TNFRSF1A
37
Show member pathways
12.29 CASP8 FADD IL1A TNF TNFRSF10A TNFRSF1A
38
Show member pathways
12.29 CASP8 FADD IL1A IL1R1 LTA TNF
39
Show member pathways
12.27 IL1A IL1R1 IL6 TNF
40
Show member pathways
12.26 CASP8 IL10 IL6 TNF
41 12.23 IL10 IL1A IL6 TNF
42
Show member pathways
12.18 CASP8 FADD TNF TNFRSF1A
43 12.18 CASP8 FADD IL10 IL10RA IL1A IL6
44 12.16 IL1A IL1R1 TNF TNFRSF1A
45 12.11 IL1A IL1R1 TNF TNFRSF1A
46
Show member pathways
12.09 CASP8 FADD TNF TNFRSF1A
47 12.09 IL10 IL1A IL6 TNF TNFRSF1B
48 12.07 IL1A IL1R1 IL6 TNF
49
Show member pathways
12.07 IL10 IL10RA IL1A IL1R1 IL6 TNFRSF10A
50
Show member pathways
12.03 CASP8 IL1A IL1R1

GO Terms for Post-Transplant Lymphoproliferative Disease

Cellular components related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 IL1R1 SLC11A1 TNF TNFRSF10A TNFRSF1A TNFRSF1B
2 cell surface GO:0009986 9.83 B2M IL1R1 TNF TNFRSF10A TNFRSF1A
3 extracellular space GO:0005615 9.76 B2M IL10 IL1A IL6 LTA TNF
4 death-inducing signaling complex GO:0031264 9.37 CASP8 FADD
5 membrane raft GO:0045121 9.35 CASP8 FADD TNF TNFRSF1A TNFRSF1B
6 CD95 death-inducing signaling complex GO:0031265 9.32 CASP8 FADD
7 extracellular region GO:0005576 9.32 B2M IL10 IL1A IL1R1 IL6 LTA
8 ripoptosome GO:0097342 9.26 CASP8 FADD

Biological processes related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 TNF TNFRSF10A TNFRSF1A TNFRSF1B
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.99 CASP8 FADD IL1A TNF TNFRSF1A TNFSF10
3 defense response to bacterium GO:0042742 9.98 IL10 SLC11A1 TNF TNFRSF1A
4 tumor necrosis factor-mediated signaling pathway GO:0033209 9.97 LTA TNF TNFRSF10A TNFRSF1A TNFRSF1B
5 positive regulation of MAPK cascade GO:0043410 9.95 IL6 TNFRSF10A TNFRSF1A TNFRSF1B
6 cellular response to lipopolysaccharide GO:0071222 9.93 IL10 IL6 TNF TNFRSF1B
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.93 CASP8 FADD TNF TNFRSF10A TNFSF10
8 positive regulation of DNA binding transcription factor activity GO:0051091 9.89 IL10 IL6 TNF
9 negative regulation of inflammatory response GO:0050728 9.89 IL10 TNFRSF1A TNFRSF1B
10 defense response to Gram-positive bacterium GO:0050830 9.89 IL6 LTA TNF
11 cellular response to mechanical stimulus GO:0071260 9.89 CASP8 FADD TNFRSF10A TNFRSF1A
12 positive regulation of interferon-gamma production GO:0032729 9.88 FADD LTA SLC11A1 TNF
13 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.86 CASP8 FADD TNFRSF10A TNFSF10
14 response to glucocorticoid GO:0051384 9.85 IL10 IL6 TNF
15 humoral immune response GO:0006959 9.84 IL6 LTA TNF
16 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.83 TNF TNFRSF1A TNFRSF1B
17 positive regulation of interleukin-6 production GO:0032755 9.83 IL1A IL6 TNF
18 extrinsic apoptotic signaling pathway GO:0097191 9.83 CASP8 FADD TNF TNFRSF10A TNFRSF1B
19 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.8 CASP8 FADD TNFRSF10A TNFSF10
20 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.79 CASP8 TNF TNFRSF1A
21 positive regulation of cytokine secretion GO:0050715 9.79 IL10 IL1A TNF
22 negative regulation of growth of symbiont in host GO:0044130 9.76 IL10 LTA TNF
23 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.76 CASP8 FADD TNFRSF10A TNFSF10
24 cytokine-mediated signaling pathway GO:0019221 9.76 IL10 IL10RA IL1A IL1R1 IL6 TNF
25 defense response to protozoan GO:0042832 9.73 IL10 SLC11A1
26 positive regulation of chemokine production GO:0032722 9.73 IL6 TNF
27 positive regulation of proteolysis GO:0045862 9.73 CASP8 FADD
28 apoptotic signaling pathway GO:0097190 9.73 CASP8 FADD TNF TNFRSF10A TNFRSF1A TNFRSF1B
29 lymph node development GO:0048535 9.72 FADD LTA
30 iron ion transport GO:0006826 9.72 B2M SLC11A1
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.72 TNF TNFRSF1B
32 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.72 CASP8 FADD TNF TNFRSF10A TNFRSF1A
33 positive regulation of macrophage differentiation GO:0045651 9.71 CASP8 FADD
34 response to molecule of bacterial origin GO:0002237 9.71 B2M IL10
35 activation of cysteine-type endopeptidase activity GO:0097202 9.71 CASP8 FADD
36 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 IL10 TNF
37 regulation of necroptotic process GO:0060544 9.7 CASP8 FADD
38 positive regulation of T cell mediated cytotoxicity GO:0001916 9.7 B2M FADD
39 toll-like receptor 3 signaling pathway GO:0034138 9.7 CASP8 FADD
40 negative regulation of lipid storage GO:0010888 9.7 IL6 TNF
41 TRAIL-activated apoptotic signaling pathway GO:0036462 9.7 CASP8 FADD TNFRSF10A
42 positive regulation of ceramide biosynthetic process GO:2000304 9.69 TNF TNFRSF1A
43 regulation of synapse organization GO:0050807 9.69 IL10 IL10RA
44 endothelial cell apoptotic process GO:0072577 9.68 IL10 TNF
45 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF TNFRSF1A
46 negative regulation of cytokine secretion involved in immune response GO:0002740 9.67 IL10 TNF
47 necroptotic signaling pathway GO:0097527 9.67 FADD TNF
48 death-inducing signaling complex assembly GO:0071550 9.67 CASP8 FADD TNF TNFRSF1A
49 positive regulation of neutrophil extravasation GO:2000391 9.66 IL1A IL1R1
50 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.65 LTA TNF

Molecular functions related to Post-Transplant Lymphoproliferative Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.88 B2M CASP8 FADD TNF TNFRSF1A TNFSF10
2 protease binding GO:0002020 9.56 FADD IL1R1 TNF TNFRSF10A
3 death receptor binding GO:0005123 9.46 CASP8 FADD
4 cytokine activity GO:0005125 9.43 IL10 IL1A IL6 LTA TNF TNFSF10
5 tumor necrosis factor receptor superfamily binding GO:0032813 9.37 FADD TNFSF10
6 tumor necrosis factor-activated receptor activity GO:0005031 9.33 TNFRSF10A TNFRSF1A TNFRSF1B
7 death effector domain binding GO:0035877 9.32 CASP8 FADD
8 tumor necrosis factor receptor binding GO:0005164 9.02 CASP8 FADD LTA TNF TNFSF10
9 protein binding GO:0005515 10.28 B2M CASP8 FADD IL10 IL10RA IL1A

Sources for Post-Transplant Lymphoproliferative Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....